A Critical Interpretive Synthesis to Develop Quality Assessment Tools for E-Cigarette Reviews: Scope and Protocol

Authors: R. O’Leary, F. Costanzo




One component of a systematic review is the quality assessment of studies to determine their inclusion or exclusion. Studies on e-cigarettes are conducted in the contentious atmosphere surrounding tobacco harm reduction, which has resulted at times in research bias. Therefore, the quality assessment of studies on e-cigarettes requires more scrutiny than what is provided by generic tools on study design. This topic-specific quality assessment must examine the tests, measurements, and analysis methods used for their adherence to research standards. Furthermore, the studies need to be carefully screened for bias. Because standard quality assessment tools do not provide this topic-specific guidance, we propose to develop quality assessment tools specifically for reviews on e-cigarettes, and for our living systematic reviews on e-cigarettes for tobacco harm reduction.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The protocol was produced with the help of a grant from the Foundation for a Smoke Free World, Inc. The contents, selection and presentation of facts, as well as any opinions expressed in the protocol are the sole responsibility of the authors and under no circumstances shall be regarded as reflecting the positions of the Foundation for a Smoke-Free World, Inc. The Grantor had no role in the selection of the research topic, study design, or the writing of the protocol or the living systematic review project.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.


The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

exempt protocol – no human subjects

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.


I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).


I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.